» Articles » PMID: 39078546

Comparison Among Different Preclinical Models Derived from the Same Patient with a Non-functional Pancreatic Neuroendocrine Tumor

Overview
Journal Hum Cell
Publisher Springer
Specialty Cell Biology
Date 2024 Jul 30
PMID 39078546
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic neuroendocrine tumors are the second most common tumors of the pancreas, and approximately half of patients are diagnosed with liver metastases. Currently, the improvement in the efficacy of relevant treatment methods is still limited. Therefore, there is an urgent need for in-depth research on the molecular biological mechanism of pancreatic neuroendocrine tumors. However, due to their relatively inert biology, preclinical models are extremely scarce. Here, the patient-derived organoid, and patient-derived xenograft were successfully constructed. These two models and the previously constructed cell line named SPNE1 all derived from the same patient with a grade 3 non-functional pancreatic neuroendocrine tumor, providing new tumor modeling platforms, and characterized using immunohistochemistry, whole-exome sequencing, and single-cell transcriptome sequencing. Combined with a tumor formation experiment in immunodeficient mice, we selected the model that most closely recapitulated the parental tumor. Overall, the patient-derived xenograft model most closely resembled human tumor tissue.

Citing Articles

Protective effects of pioglitazone in renal ischemia-reperfusion injury (RIRI): focus on oxidative stress and inflammation.

Golmohammadi M, Sadeghi Ivraghi M, Hasan E, Huldani H, Zamanian M, Rouzbahani S Clin Exp Nephrol. 2024; 28(10):955-968.

PMID: 38935212 DOI: 10.1007/s10157-024-02525-3.

References
1.
Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L . The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Neuroendocrinology. 2016; 104(1):85-93. DOI: 10.1159/000445165. View

2.
Gullo L, Migliori M, Falconi M, Pederzoli P, Bettini R, Casadei R . Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol. 2003; 98(11):2435-9. DOI: 10.1111/j.1572-0241.2003.07704.x. View

3.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y . Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017; 3(10):1335-1342. PMC: 5824320. DOI: 10.1001/jamaoncol.2017.0589. View

4.
Shi X, Li Y, Yuan Q, Tang S, Guo S, Zhang Y . Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Nat Commun. 2022; 13(1):2169. PMC: 9023604. DOI: 10.1038/s41467-022-29857-6. View

5.
Yang Z, Zhang L, Serra S, Law C, Wei A, Stockley T . Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft. Endocr Pathol. 2016; 27(2):97-103. DOI: 10.1007/s12022-016-9429-4. View